Cochlear

Cochlear CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Cochlear (COH.AX) as of Oct 8, 2026 is 16.60 %. In the previous year, CapEx to Operating Cash Flow Ratio was 26.26 % — a change of -36.78% (lower).

CapEx/OCF

16.60 %

YoY

-36.78%

Last updated:

CapEx to Operating Cash Flow Ratio of Cochlear is 2026 16.60 % . CapEx to Operating Cash Flow Ratio of Cochlear was 2025 26.26 % . It decreases by -36.78% lower compared to the previous year.

The Cochlear CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2019
20.24 AUD
Jan 1, 2020
-82.70 AUD
Jan 1, 2021
25.13 AUD
Jan 1, 2022
20.50 AUD
Jan 1, 2023
26.46 AUD
Jan 1, 2024
16.05 AUD
Jan 1, 2025
26.26 AUD
Jan 1, 2026
16.60 AUD
The Cochlear CapEx/OCF history
YEARCapEx/OCFYoY
16.60 %-36.78%
26.26 %+63.64%
16.05 %-39.35%
26.46 %+29.06%
20.50 %-18.41%
25.13 %-130.39%
-82.70 %-508.67%
20.24 %+83.91%
11.00 %-46.57%
20.59 %+32.09%
15.59 %+23.10%
12.66 %-39.95%
21.09 %—
Access this data via the Eulerpool API

Cochlear Stock analysis

What does Cochlear do? Cochlear Ltd is an Australian-based medical technology company founded in 1981 by engineer Professor Graeme Clark. The company specializes in Cochlear implant systems and other hearing devices. Cochlear Ltd offers accessories, services, and rehabilitation training for individuals with hearing impairments. The company's products are available for both children and adults with varying degrees of hearing loss. Cochlear Ltd operates in different sectors, including Cochlear implant systems, hearing aids, and wireless accessories and streaming systems under the brand names Nucleus® and Baha®. Nucleus® systems utilize a fully implantable cochlear implant and external speech processor to convert sound into electrical signals for interpretation by the brain. Baha® systems are bone-anchored hearing devices for individuals with unilateral to moderate hearing impairments. Cochlear Ltd also provides wireless accessories and streaming systems to connect devices like mobile phones, TVs, and music players to the hearing aids and cochlear implants, improving hearing performance and enhancing social lives. The company has a strong global presence, operating in over 100 countries with headquarters in Australia, multiple production facilities, and research centers. Cochlear Ltd has received numerous awards and recognition for its products and services and is committed to researching and developing new therapies and technologies to improve the lives of individuals with hearing impairments. Cochlear is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cochlear stock

CapEx to Operating Cash Flow Ratio of Cochlear is 16.60 % in 2026.

CapEx to Operating Cash Flow Ratio of Cochlear changed from 26.26 % to 16.60 %, representing a -36.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Cochlear since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Cochlear with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

Cash Flow — Cochlear

All Key Metrics — Cochlear